125742 S13 M5 5351 c4591001 narrative 1226 12262255

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

4

Document text

Compound: PF -07302048; Protocol: C4591001 Page 1of 4
Reason(s) for Narrative: HIV
Unique Subject ID: C4591001 1226 12262255; Country: Brazil
Vaccine Group (as Administered): BNT162b2 (30 μg)
Date of First Dose: 16OCT2020; Date of Last Dose: 06NOV2020
=============================================================================================================
=============
PFIZER CONFIDENTIAL  SDTM Creation: 25MAR2021 (23:24)  Source Data: dm, vs, mh, ex, ae, cm, ds  Output File: 
./nda2_unblinded/C4591001_HIV/profile  Date of Generation: 12JUL2021 (13:23)Demography
Date of Birth Age at Enrollment (Years) Race Ethn icity Sex
1972 48 White Hispanic/Latino M
Vital Signs -Baseline
Height Weight BMIDate Collected
(Study Day)
173.8 cm 95.6 kg 31.6 kg/m2 16OCT2020 (1)
Medical History
Investigator Text MedDRA Preferred Term Start Date Disease Status
HIV HIV test positive 2010 Present
Obesity Obesity 2010 Present
contact dermatitis Dermatitis contact 2017 Present
090177e1978a4cfc\Final\Final On: 13-Jul-2021 01:22 (GMT)
(b) (6)
FDA-CBER-2021-5683-0651243
Compound: PF -07302048; Protocol: C4591001 Page 2of 4
Reaso n(s) for Narrative: HIV
Unique Subject ID: C4591001 1226 12262255; Country: Brazil
Vaccine Group (as Administered): BNT162b2 (30 μg)
Date of First Dose: 16OCT2020; Date of Last Dose: 06NOV2020
=============================================================================================================
=============
PFIZER CONFIDENTIAL  SDTM Creation: 25MAR2021 (23:24)  Source Data: dm, vs, mh, ex, ae, cm, ds  Output File: 
./nda2_unblinded/C459 1001_HIV/profile  Date of Generation: 12JUL2021 (13:23)Study Vaccination(s)
Vaccination Number Vaccine Vaccination Date (Study Day) Time of Vaccination
1 BNT162b2 16OCT2020 (1) 14:00
2 BNT162b2 06NOV2020 (22) 12:22
Adverse Events
AE 
NumberMedDRA 
SOCMedDRA Preferred 
Term Investigator TextStart Date
(Study Day)Start
TimeStop Date
(Study Day)Stop 
Time
1 GENRL Chills Chills 06NOV2020 (22) 23:00 08NOV2020 (24)
2 GENRL Injection site pain Pain at the injection site 06NOV2020 (22) 23:00 08NOV2020 (24)
3 MUSC Myalgia Muscle pain 06NOV2020 (22) 23:00 08NOV2020 (24)
4 MUSC Myalgia muscle pain 19OCT2020 (4) 22OCT2020 (7)
5 GASTR Nausea Nauseas 06NOV2020 (22) 23:00 08NOV2020 (24)
6 GENRL Pyrexia Fever 39 C 06NOV2020 (22) 23:00 08NOV2020 (24)
7 GASTR Vomiting Vomiting 06NOV2020 (22) 23:00 08NOV2020 (24)
Adverse Events
AE 
NumberDuration
(Days)Toxicity 
GradeAction 
to 
Subject SAE AE Still Present? AE Related To:Prior 
Vaccination
NumberRelative 
Day From 
Prior
VaccinationNarrative
Event
1 3 3 N N Resolved (08NOV2020) Study Treatment 2 1 N
2 3 3 N N Resol ved (08NOV2020) Study Treatment 2 1 N
090177e1978a4cfc\Final\Final On: 13-Jul-2021 01:22 (GMT)
FDA-CBER-2021-5683-0651244
Compound: PF -07302048; Protocol: C4591001 Page 3of 4
Reason(s) for Narrative: HIV
Unique Subject ID: C4591001 1226 12262255; Country: Brazil
Vaccine Group (as Administered): BNT162b2 (30 μg)
Date of First Dose: 16OCT2020; Date of Last Dose: 06NOV2020
=============================================================================================================
=============
PFIZER CONFIDENTIAL  SDTM Creation: 25MAR2021 (23:24)  Source Data: d m, vs, mh, ex, ae, cm, ds  Output File: 
./nda2_unblinded/C4591001_HIV/profile  Date of Generation: 12JUL2021 (13:23)Adverse Events
AE 
NumberDuration
(Days)Toxicity 
GradeAction 
to 
Subject SAE AE Still Present? AE Related To:Prior 
Vaccination
NumberRelative 
Day From 
Prior
VaccinationNarrative
Event
3 3 3 TC N Resolved (08NOV2020) Study Treatment 2 1 N
4 4 2 TC N Resolved (22OCT2020) Study Treatment 1 4 N
5 3 3 N N Resolved (08NOV2020) Study Treatment 2 1 N
6 3 3 TC N Resolved (08NOV2020) Study Treatment 2 1 N
7 3 3 TC N Resolved (08NOV2020) Study Treatment 2 1 N
Prohibited Concomitant Medications
No Prohibited Concomitant Medications
Nonstudy Vaccines
No Nonstudy Vaccines
090177e1978a4cfc\Final\Final On: 13-Jul-2021 01:22 (GMT)
FDA-CBER-2021-5683-0651245
Compound: PF -07302048; Protocol: C4591001 Page 4of 4
Reason(s) for Narrative: HIV
Unique Subject ID: C4591001 1226 12262255; Country: Brazil
Vaccine Group (as Administered): BNT162b2 (30 μg)
Date of First Dose: 16OCT2020; Date of Last Dose: 06NOV2020
=============================================================================================================
=============
PFIZER CONFIDENTIAL  SDTM Creation: 25MAR2021 (23:24)  Source Data: dm, vs, mh, ex, ae, cm, ds  Output File: 
./nda2_unblinded/C459 1001_HIV/profile  Date of Generation: 12JUL2021 (13:23)Subject Summary
Status Study PhaseWithdrawal/Completion 
DateReason for 
Withdrawal
Completed SCREENING 16OCT2020
Completed VACCINATION 06JAN2021
REPEAT SCREENING 1
OPEN LABEL 
TREATMENT
FOLLOW -UP
090177e1978a4cfc\Final\Final On: 13-Jul-2021 01:22 (GMT)
FDA-CBER-2021-5683-0651246